VTRS Stock Analysis — Viatris
Sector: Healthcare
AI Verdict
Viatris is cheap for the growth you're getting, but the low multiple reflects skepticism that its scale moat can deliver more than flat results.
Competitive Moat
Viatris operates a global generics and specialty pharmaceutical platform, leveraging a vast manufacturing and distribution network to supply essential medicines at scale. Its moat comes from regulatory expertise and cost efficiencies that make it hard for smaller competitors to match its breadth or pricing.
Summary
Viatris trades at a rock-bottom 6.2x forward earnings, drawing attention for its deep value in a defensive sector.
Where It Stands
With a forward P/E of 6.2x versus the healthcare median of 22x and trailing revenue growth of just 1.6%, the stock is priced for minimal growth and high uncertainty.
Key Metrics
- Forward P/E: 6.2x
- Revenue Growth: +0.0%
- Dividend Yield: 0.03%
- 52-Week High: $17.53
- 52-Week Low: $8.63
Analyst Consensus
12 Buy · 5 Hold · 1 Sell (18 analysts)
Bull Case
The 6.2x forward P/E is extremely cheap relative to the sector, leaving room for upside if even modest growth or capital returns materialize.
Bear Case
If the market rerates VTRS to an 8x multiple (still below sector median), shares could fall by over 20% from here.
Catalyst to Watch
Watch for regulatory approvals or cost-cutting updates, as either could quickly shift sentiment given the low valuation baseline.